CD9 Biomarker Targeting to Block PEC Migration in Glomerular Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms underlying the invasion of glomerular parietal epithelial cells (PECs) into the glomerulus, leading to glomerular damage and irreversible renal failure in diseases like necrotizing crescentic glomerulonephritis (CGN) and focal segmental glomerulosclerosis (FSGS), are poorly understood.
Innovation Solution
The increased expression of CD9 in PECs is identified as a key driver of glomerular damage, and targeting the CD9 gene or administering CD9 inhibitors prevents PEC migration and expression of CD44 and β1 integrin, offering a therapeutic approach to treat these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD9 targeting is applied to prevent PEC migration and glomerular damage, then renal function is preserved, but the mechanism of action is not yet fully understood
Solution Approach 1:
The patent identifies CD9 as an intermediary molecule that mediates the interaction between PECs and the glomerular basement membrane. By targeting CD9, the patent blocks the migratory capacity of PECs, thereby preventing glomerular damage. This intermediary approach allows therapeutic intervention without requiring complete understanding of all downstream signaling pathways.
2Reliability
If CD9 inhibitors are administered to block PEC invasion, then glomerular damage is prevented, but specificity of targeting may affect other CD9-expressing cells
Solution Approach 1:
The patent exploits the local quality difference in CD9 expression patterns between glomerular parietal epithelial cells and other cell types. By designing inhibitors that specifically target the CD9 isoform or expression pattern characteristic of activated PECs, the patent achieves selective inhibition of glomerular invasion while sparing other CD9-expressing cells such as platelets and cancer cells.
3Loss of time
If early diagnosis through CD9 detection is implemented, then treatment timing is improved, but detection sensitivity in early stages may be limited
Solution Approach 1:
The patent employs preliminary action by detecting CD9 upregulation in PECs as an early biomarker before significant glomerular damage occurs. This early detection capability allows for timely intervention at the stage when CD9 is first upregulated, preventing progression to irreversible renal failure. The method includes detecting CD9 in urine or serum samples as a non-invasive early diagnostic tool.
Data Source
AI summary
The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.